NASDAQ: RVMDRevolution Medicines Inc Stock
$36.76+0.56 (+1.55%)
Updated Apr 17, 2025
RVMD Price
$36.76
Fair Value Price
$2.43
Market Cap
$6.83B
52 Week Low
$29.17
52 Week High
$62.40
P/E
-10.27x
P/B
3.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$600.09M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$557M
Beta
1.37
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RVMD Overview
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RVMD's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RVMD
Ranked#416 of 463
Ranked#416 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important RVMD news, forecast changes, insider trades & much more!
RVMD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RVMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RVMD ($36.76) is overvalued by 1,414.17% relative to our estimate of its Fair Value price of $2.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RVMD ($36.76) is not significantly undervalued (1,414.17%) relative to our estimate of its Fair Value price of $2.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RVMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RVMD due diligence checks available for Premium users.
Valuation
RVMD fair value
Fair Value of RVMD stock based on Discounted Cash Flow (DCF)
Price
$36.76
Fair Value
$2.43
Overvalued by
1,414.17%
RVMD ($36.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RVMD ($36.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RVMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RVMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.27x
Industry
-177.72x
Market
27.98x
RVMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.02x
Industry
4.05x
RVMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RVMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$194.6M
Profit Margin
0%
RVMD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.6B
Liabilities
$293.1M
Debt to equity
0.13
RVMD's short-term assets ($2.33B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RVMD's short-term assets ($2.33B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RVMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RVMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$138.3M
Investing
-$392.9M
Financing
$873.8M
RVMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RVMD vs Biotech Stocks
Revolution Medicines Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.